Close Menu
Trending
mercoledì 6 Novembre 2024
Abbonati
Abbonati
Agenparl English

Patient Listening Session Summaries

RedazioneBy Updated:Nessun commento6 Mins Read
Logo (AGENPARL) - Roma, 17 Marzo 2023

(AGENPARL) – SILVER SPRING ven 17 marzo 2023

Photo montage of people looking at computers

FDA’s Patient Affairs is responsible for managing the Agency’s Patient Listening Session program.

This page contains a list of all the Patient Listening Sessions that have been organized to date. This page is updated frequently with meeting summaries from each Patient Listening Session as they become available.

Patient Listening Sessions can either be FDA-requested (where FDA has a specific set of questions to ask) or patient-led (when a patient community wants to share their perspectives with the FDA). Only the FDA, patients, caregivers, and advocates participate in the session.

For more information on FDA’s Patient Listening Session program how to request a Patient Listening Session, contact Patient Affairs or click here.

Previously Conducted Patient Listening Sessions

FDA-Requested Patient Listening Session Summaries

Patient-Led Listening Session Summaries

 Learn more about Patient Listening Sessions:

How does FDA benefit from Patient Listening Sessions?

How do I request a Patient Listening Session?

How do I prepare for a Patient Listening Session?

What happens after a Patient Listening Session?

Patient Listening Sessions – Home

Read about the procedures for the management of Patient Listening Sessions by the Office of Patient Affairs in Staff Manual Guide 9006.

Discussions in Patient Listening Sessions are informal. All opinions, recommendations, and proposals are unofficial and nonbinding on FDA and all other participants.

Resources (e.g., funding): It is the patient organization’s decision if they are able to plan and hold a Patient Listening Session for their community. Planning can be done with minimum expense to the organization (e.g., FDA does not encourage using event planners, consultants, scientific writers, or other external resources on your team, especially when resources (e.g., funding) may be limited). For transparency, the patient organization should identify any financial sponsors and any subsequent Patient Listening Session materials. The patient organization and other planning team members and collaborators are also encouraged to share any interactions (financial and non-financial) that may be related to planning and conduct of the Patient Listening Session. All decisions made for the Patient Listening Session (e.g., development of agenda, discussion, selection of patient participants) should only be done by the patient organization. Input from medical product sponsors is not encouraged.

Disclaimer: Our website has links to other organizations. You should be aware that:

  • The disclaimer graphic notice means that you are leaving the U.S. Food and Drug Administration (FDA) site and entering a non-federal website.

  • This external link provides additional information that is consistent with the intended purpose of the FDA site.

  • The FDA cannot attest to the accuracy of information provided by this link.

  • Linking to a non-federal site does not constitute an endorsement by FDA or any of its employees of the sponsors or the information and products presented on the site.

  • You will be subject to the destination site’s privacy policy when you leave the FDA site.

20https://thevedsmovement.org/wp-content/uploads/2020/10/FDA-Patient-Listening-Session-Meeting-Summary-Final.pdf’>https://thevedsmovement.org/wp-content/uploads/2020/10/FDA-Patient-Listening-Session-Meeting-Summary-Final.pdf

Fonte/Source: http://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-listening-session-summaries

Share.

Related Posts

Comments are closed.

CHI SIAMO

L’Agenzia di Stampa Parlamentare Agenparl è una delle voci storiche ed autorevoli dell’informazione italiana parlamentare ed è una delle principali news company italiane. Nel 1950 Francesco Lisi fondò la più antica Agenzia giornalistica parlamentare italiana, con il nome di S.P.E.; con l’ingresso nell’ASP (Associazione stampa parlamentare) nel 1953 ne mutò il nome in Agenparl.

Dal 1955 affianca con i suoi notiziari il mondo istituzionale, editoriale, economico e finanziario, diventando oggi una tra le fonti più autorevoli dell’informazione con i propri prodotti, servizi e soluzioni all’avanguardia. Dal 2009 il Direttore è Luigi Camilloni che ha proseguito lungo la strada tracciata da Lisi e cioè quella che da sempre ha contraddistinto l’Agenzia, ossia l’imparzialità.

Una formula editoriale veloce ed innovativa che garantisce un’informazione puntuale e degli approfondimenti originali. Per noi di Agenparl, fare informazione significa mantenere un alto livello di esattezza, obiettività e imparzialità, attraverso un codice linguistico chiaro, ma soprattutto senza far ricorso a formule e luoghi comuni giornalistici.

CONTATTI

Per inviare i comunicati stampa:

redazione@agenparl.eu

 

Per informazioni:

marketing@agenparl.eu

 

Uff. (+39) 06 93 57 9408

Cell. (+39) 340 681 9270

Facebook Twitter Youtube Instagram Linkedin Whatsapp

SERVIZI

Agenparl dispone di contenuti, servizi e strumenti a cui si affidano Enti, Istituzioni ed Università, sviluppando una serie di soluzioni personalizzabili a seconda delle necessità dei clienti.

NOTIZIARIO

Per tutti i servizi scrivere a
marketing@agenparl.eu

©  Tutti i diritti e contenuti sono di Agenparl